C07C2602/18

Prodrug of amino acid derivative

Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on. ##STR00001##

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Ladderane Lipid Compounds and Liposomes and Methods of Preparing and Using the Same

Methods for preparing a variety of ladderane precursors, ladderane compounds and ladderane lipids are provided. Also provided are methods of preparing a liposome from the ladderane lipids disclosed herein, and compositions thereof. Aspects of the invention include encapsulated one or more cargo moieties in the liposome or compositions thereof and use of the subject liposome compositions as vehicles in drug delivery, imaging, diagnostics and other medical applications. Aspects of the methods disclosed herein include administering a liposomal composition comprising a pharmaceutical agent to a subject under conditions sufficient to deliver the composition to a site of interest in the subject, and release the pharmaceutical agent from the liposomal composition.

CYCLOPROPANATION OF SUBSTITUTED ALKENES

Disclosed is a cyclopropanation process comprising the step of reacting an alkene compound having at least one carbon-carbon double bond with at least one dihaloalkane. The reaction is carried out in the presence of (i) particulate metal Zn, (ii) catalytically effective amount of particulate metal Cu or a salt thereof, (iii) at least one haloalkylsilane, and (iv) at least one solvent.

ORGANIC COMPOUND, ELECTRONIC COMPONENT AND ELECTRONIC APPARATUS COMPRISING THE SAME
20240206326 · 2024-06-20 ·

The present application relates to the technical field of organic materials and provides an organic compound, an electronic component and an electronic apparatus containing the organic compound. The organic compound has a structure shown in Formula 1. The organic compound, when used in an organic electroluminescent device, can improve the performance of the device.

Acetate compounds useful as odorants
12012570 · 2024-06-18 · ·

The present invention refers to acetates possessing woody creamy sandalwood olfactory properties. The invention further refers to fragrance compositions and consumer products comprising them.

Organic compound, electronic component and electronic apparatus comprising the same

The present application relates to the technical field of organic materials and provides an organic compound, an electronic component and an electronic apparatus containing the organic compound. The organic compound has a structure shown in Formula 1. The organic compound, when used in an organic electroluminescent device, can improve the performance of the device. ##STR00001##

Cyclopropanation of substituted alkenes

Disclosed is a cyclopropanation process comprising the step of reacting an alkene compound having at least one carbon-carbon double bond with at least one dihaloalkane. The reaction is carried out in the presence of (i) particulate metal Zn, (ii) catalytically effective amount of particulate metal Cu or a salt thereof, (iii) at least one haloalkylsilane, and (iv) at least one solvent.

PRODRUG OF AMINO ACID DERIVATIVE

Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof.

More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

##STR00001##